Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
KB3g2CmNkNEYwPW4
